Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SZC passes extension test for hyperkalemia

Key clinical point: SZC controlled hyperkalemia with a tolerable risk profile.

Major finding: 88.3% achieved mean serum potassium of 5.1 mmol/L or less.

Study details: Open-label extension study of 123 patients.

Disclosures: The study was funded by AstraZeneca.


Roger SD et al. Am J Nephrol;2019:50(6):473-80.